These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

164 related items for PubMed ID: 18268187

  • 1. Effect of low concentrations of apomorphine on parkinsonism in a randomized, placebo-controlled, crossover study.
    Gunzler SA, Koudelka C, Carlson NE, Pavel M, Nutt JG.
    Arch Neurol; 2008 Feb; 65(2):193-8. PubMed ID: 18268187
    [Abstract] [Full Text] [Related]

  • 2. Foot-tapping rate as an objective outcome measure for Parkinson disease clinical trials.
    Gunzler SA, Pavel M, Koudelka C, Carlson NE, Nutt JG.
    Clin Neuropharmacol; 2009 Feb; 32(2):97-102. PubMed ID: 18978495
    [Abstract] [Full Text] [Related]

  • 3. Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.
    Deleu D, Hanssens Y, Northway MG.
    Drugs Aging; 2004 Feb; 21(11):687-709. PubMed ID: 15323576
    [Abstract] [Full Text] [Related]

  • 4. Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial.
    Katzenschlager R, Poewe W, Rascol O, Trenkwalder C, Deuschl G, Chaudhuri KR, Henriksen T, van Laar T, Spivey K, Vel S, Staines H, Lees A.
    Lancet Neurol; 2018 Sep; 17(9):749-759. PubMed ID: 30055903
    [Abstract] [Full Text] [Related]

  • 5. Pharmacodynamics of levodopa coadministered with apomorphine in parkinsonian patients with end-of-dose motor fluctuations.
    Baas H, Harder S, Bürklin F, Demisch L, Fischer PA.
    Clin Neuropharmacol; 1998 Sep; 21(2):86-92. PubMed ID: 9579293
    [Abstract] [Full Text] [Related]

  • 6. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.
    Chen JJ, Obering C.
    Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444
    [Abstract] [Full Text] [Related]

  • 7. Apomorphine tolerance in Parkinson's disease: lack of a dose effect.
    Gancher ST, Woodward WR, Nutt JG.
    Clin Neuropharmacol; 1996 Feb; 19(1):59-64. PubMed ID: 8867518
    [Abstract] [Full Text] [Related]

  • 8. Effects of a dopamine agonist on the pharmacodynamics of levodopa in Parkinson disease.
    Brodsky MA, Park BS, Nutt JG.
    Arch Neurol; 2010 Jan; 67(1):27-32. PubMed ID: 20065126
    [Abstract] [Full Text] [Related]

  • 9. Effects of methylphenidate on response to oral levodopa: a double-blind clinical trial.
    Nutt JG, Carter JH, Carlson NE.
    Arch Neurol; 2007 Mar; 64(3):319-23. PubMed ID: 17353373
    [Abstract] [Full Text] [Related]

  • 10. A Randomized Controlled Trial of Subcutaneous Apomorphine for Parkinson Disease: A Repeat Dose and Pharmacokinetic Study.
    Nomoto M, Kubo S, Nagai M, Yamada T, Tamaoka A, Tsuboi Y, Hattori N, PD Study Group.
    Clin Neuropharmacol; 2015 Mar; 38(6):241-7. PubMed ID: 26536022
    [Abstract] [Full Text] [Related]

  • 11. [Continuous subcutaneous infusion of apomorphine in Parkinson's disease: retrospective analysis of a series of 81 patients].
    Rambour M, Moreau C, Salleron J, Devos D, Kreisler A, Mutez E, Simonin C, Annic A, Dujardin K, Destée A, Defebvre L.
    Rev Neurol (Paris); 2014 Mar; 170(3):205-15. PubMed ID: 24594365
    [Abstract] [Full Text] [Related]

  • 12. Effective delivery of apomorphine in the management of Parkinson disease: practical considerations for clinicians and Parkinson nurses.
    Bhidayasiri R, Chaudhuri KR, LeWitt P, Martin A, Boonpang K, van Laar T.
    Clin Neuropharmacol; 2015 Mar; 38(3):89-103. PubMed ID: 25970277
    [Abstract] [Full Text] [Related]

  • 13. Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study.
    Olanow CW, Factor SA, Espay AJ, Hauser RA, Shill HA, Isaacson S, Pahwa R, Leinonen M, Bhargava P, Sciarappa K, Navia B, Blum D, CTH-300 Study investigators.
    Lancet Neurol; 2020 Feb; 19(2):135-144. PubMed ID: 31818699
    [Abstract] [Full Text] [Related]

  • 14. [Treatment of apomorphine infusion adverse effects: subcutaneous nodules and neuropsychiatric complications].
    Giménez de Béjar V, Carballo-Cordero M.
    Rev Neurol; 2012 Feb; 55 Suppl 1():S25-9. PubMed ID: 23169230
    [Abstract] [Full Text] [Related]

  • 15. Literature review: intermittent subcutaneous apomorphine therapy in Parkinson's disease.
    Factor SA.
    Neurology; 2004 Mar 23; 62(6 Suppl 4):S12-7. PubMed ID: 15037666
    [Abstract] [Full Text] [Related]

  • 16. Levodopa-induced dyskinesias and continuous subcutaneous infusions of apomorphine: results of a two-year, prospective follow-up.
    Kanovský P, Kubová D, Bareš M, Hortová H, Streitová H, Rektor I, Znojil V.
    Mov Disord; 2002 Jan 23; 17(1):188-91. PubMed ID: 11835461
    [Abstract] [Full Text] [Related]

  • 17. A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events.
    Dewey RB, Hutton JT, LeWitt PA, Factor SA.
    Arch Neurol; 2001 Sep 23; 58(9):1385-92. PubMed ID: 11559309
    [Abstract] [Full Text] [Related]

  • 18. Stepwise intravenous infusion of apomorphine to determine the therapeutic window in patients with Parkinson's disease.
    van Laar T, van der Geest R, Danhof M, Boddé HE, Goossens PH, Roos RA.
    Clin Neuropharmacol; 1998 Sep 23; 21(3):152-8. PubMed ID: 9617506
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Subcutaneous continuous apomorphine infusion: treatment initiation and follow up].
    Grandas FJ, Sesar-Ignacio Á.
    Rev Neurol; 2012 Sep 23; 55 Suppl 1():S21-4. PubMed ID: 23169229
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.